The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 45 | — | 20.1x | Near average | |
Growth | 76 | 47.5% | 5.6% | Above average | |
Quality | 37 | -153.0% | 7.6% | Near average | |
Safety | 35 | 1.1x | 0.4x | Near average | |
Capital Return | 41 | — | 2.19% | Near average | |
Momentum | — | — | — | No data | |
Sentiment | — | — | — | No data |
Ionis Pharmaceuticals, Inc. is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy Ionis Pharmaceuticals, Inc. shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.
AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
Ionis stock has seen notable stability in its average price target at $107.27 over the past month, despite 4 new analysts initiating coverage, bringing the total number of analysts to 12. This consistency in consensus despite the increased number of opinions reflects stable institutional optimism, especially with a significant positive price gap between the current price ($73.82) and the lowest recorded price target ($87).
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.